At the 65th annual American Crystallographic Association 2015 meeting in Philadelphia this week, a team from the Rockville, Md.-based National Cancer Institute presented three newly determined crystal structures that collectively provide a starting point for a drug-design effort to combat MERS.
The researchers anticipate it will take at least a year to sort through the data and begin the actual drug design. However, this method could lead to a drug that is easily administered orally, a stumbling block that has limited the appeal of other types of antiviral medications developed for the same purpose.
More articles on infection control:
46 hospitals with the fastest patient aid
Infection preventionists approve 11 C. diff prevention recommendations
US News names Best Hospitals: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
